Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada
- Clinique Medicale du Quartier Latin
-
Montreal, Quebec, Canada
- Clinique Medicale L'Actuele
-
Montreal, Quebec, Canada
- Dr Roger P Leblanc
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35203
- Sorra Research Ctr / Med Forum
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Body Positive
-
-
California
-
Los Angeles, California, United States, 900276069
- Aids Healthcare Foundation
-
San Francisco, California, United States, 94115
- San Francisco Gen Hosp
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- Med Alternatives
-
Pembrook, Florida, United States, 33023
- County Line Med CtrInc
-
Vero Beach, Florida, United States, 32960
- Dr Gerald Pierone Jr
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- The CORE Ctr
-
-
Indiana
-
Indianapolis, Indiana, United States, 462025250
- Indiana Univ Med Ctr
-
-
Kansas
-
Wichita, Kansas, United States, 672143124
- Univ of Kansas School of Medicine
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hosp
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Med Ctr
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- NJCRI
-
Somerville, New Jersey, United States, 08876
- Infectious Disease Assoc of Central Jersey
-
-
Ohio
-
Columbus, Ohio, United States, 432101228
- Ohio State Univ Hosp Clinic
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Anderson Clinical Research
-
-
Texas
-
Dallas, Texas, United States, 75235
- Univ of Texas Southwestern Med Ctr of Dallas
-
Houston, Texas, United States, 77004
- Gathe, Joseph, M.D.
-
Houston, Texas, United States, 77006
- Montrose Clinic
-
-
Virginia
-
Hampton, Virginia, United States, 23666
- Hampton Roads Med Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients may be eligible for this study if they:
- Are HIV-positive.
- Have a viral load of at least 2,000 copies/ml and a CD4 count of at least 200 cells/mm3.
- Are at least 18 years old.
- Agree to practice sexual abstinence or to use effective barrier methods of birth control (such as condoms).
Exclusion Criteria
Patients will not be eligible for this study if they:
- Have had severe diarrhea within 30 days of study entry.
- Have a history of pancreatic disease or any other serious condition.
- Have hepatitis within 30 days of study entry.
- Are diagnosed with an opportunistic (AIDS-related) infection at the time of enrollment.
- Are unable to take medications by mouth.
- Have received certain medications.
- Are pregnant or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Parallel Assignment
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Gathe J, Badero R, Grimwood A, Abrams L, Klesczewski K, Mclaren C. AI454152: Comparison of a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine Administered Once-Daily Versus a Regimen of Combivir Plus Nelfinavir. 8th Conference on Retroviruses and Opportunistic Infections, 2001 Feb 4-8. (abstract no 319)
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Protease Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Lamivudine
- Zidovudine
- Stavudine
- Didanosine
- Nelfinavir
- Lamivudine, zidovudine drug combination
Other Study ID Numbers
Other Study ID Numbers
- 039F
- AI454-152
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.